Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Resonance Health Ltd ( (AU:RHT) ) just unveiled an update.
Resonance Health Ltd announced that it will release its half-year results for the period ending 31 December 2024, on or before 28 February 2025, via the Australian Securities Exchange. The company will host a conference call on the same day, led by its CEO and CFO, to discuss these results with investors and analysts. This move reflects the company’s transparency and engagement with its stakeholders, potentially impacting its industry position by reinforcing its commitment to shareholder communication.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company that provides globally recognized quantitative assessments essential for managing diseases and drug development. The company is noted for its regulatory clearances for Software-as-Medical Devices (SaMDs) across the USA, Europe, UK, and Australia, and holds ISO 13485 certification. Its products, which incorporate Artificial Intelligence, include FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, LiverSmart®, and CardiacT2* among others, aimed at assessing various health conditions non-invasively.
YTD Price Performance: 10.0%
Average Trading Volume: 251,859
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$25.28M
Find detailed analytics on RHT stock on TipRanks’ Stock Analysis page.
